Background: Geographic variations in use of medical services have been interpreted as indirect evidence of wasteful care. Less overuse of services, however, may not be reliably associated with less geographic variation.
G
eographic variations in use of medical care that are neither explained by patient characteristics nor associated with better outcomes have been interpreted as evidence of considerable waste in the U.S. health care system (1, 2) . A recent Institute of Medicine study, however, concluded that policies targeting high-use areas may not effectively foster more efficient care even if they reduce geographic variation (3-5). Because specific instances of overuse are challenging to measure directly (6, 7) , geographic comparisons of risk-adjusted service use may nevertheless remain an appealing indirect approach to gauging the extent of wasteful practices. Thus, an important question not directly addressed by the Institute of Medicine study is whether a health care system achieving less overuse should necessarily exhibit less variation. Is geographic variation in service use a reliable correlate of the amount of overuse in a health care system?
To address this question, we compared the use of cancer-related imaging in traditional fee-for-service Medicare and the Department of Veterans Affairs (VA) health care system-an instructive test case for several reasons. Since its transformation in the 1990s, the VA health care system has emphasized features of payment and delivery systems currently encouraged by Medicare, including accountability, integrated care delivery, quality measurement, performance incentives, and global budgets (8 -13) . The VA health care system generally performs as well as or better than Medicare on measures of cancer care quality (14, 15) , which is consistent with comparisons of other quality measures and outcomes between VA and non-VA patients (16 -20) . Thus, evidence of lower spending on cancer care in the VA system, particularly on frequently overused services, would suggest more efficient care. Use of advanced imaging for patients with cancer has grown over recent decades and is a major focus of the American Society of Clinical Oncology's contribution to the American Board of Internal Medicine Foundation's Choosing Wisely list of common practices not supported by current evidence (21) (22) (23) (24) . Finally, cancer care may be more concentrated within the VA than other types of care (25) (26) (27) , thereby supporting clearer distinctions in system performance between the VA and Medicare.
Using 2003 to 2005 Medicare claims and VA utilization data linked to cancer registry data for older men with lung, colorectal, or prostate cancer, we tested whether use of cancer-related imaging was lower for VA patients than for traditional Medicare beneficiaries and, if so, whether lower average use was associated with less geographic variation. Drawing from the Choosing Wisely recommendations (24) , we also compared the 2 systems' performance on a direct measure of cancer imaging overuse.
METHODS

Study Cohorts and Data Sources
We studied men older than 65 years with lung, colorectal, or prostate cancer first diagnosed in 2003 to 2004. Patients were identified from the VA Central Cancer Registry (the VA cohort) or the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute (the Medicare cohort).
The VA Central Cancer Registry collects uniformly reported information on demographic and tumor characteristics for all VA patients receiving a diagnosis of, or first course of treatment of, an invasive cancer at a VA medical center. The SEER population-based cancer registries collect similar information for patients with incident cancer in areas covering 28% of the U.S. population (28). For the VA cohort, we obtained linked Veterans Health Administration data on health care utilization and Medicare enrollment and claims data through 2005, as described previously (14, 29) . For the Medicare cohort, we obtained linked Medicare enrollment files and claims through 2005 (30) . For both cohorts, we assessed vital status through 2005 using National Death Index linkages.
We limited analyses to 40 hospital referral regions (HRRs) with complete or partial coverage by cancer registries in the SEER program, 1 or more VA medical centers, and 20 or more person-years of data for the Medicare and VA cohorts. The 40 HRRs covered 22% of the Medicare population in 2005 (31) and spanned 23 states (Appendix Table 1 , available at www.annals.org). We excluded patients from both cohorts who were enrolled in Medicare managed care plans in the year before diagnosis, and we further restricted the Medicare cohort to patients continuously enrolled in Medicare Parts A and B in that year so that preexisting comorbid conditions could be assessed using the Klabunde modification of the Charlson comorbidity index (32, 33) . During the 2003 to 2005 study period, we excluded person-years in which patients in either cohort were enrolled in Medicare managed care plans. Finally, we excluded a small number (0.6%) of Medicare and VA patients with cancer diagnosed after death or with no utilization data from 45 days before, through 195 days after, diagnosis (suggesting inaccurate linkage) (14, 29) .
For both cohorts, age, race/ethnicity, marital status, cancer type, stage, grade, and an indicator of prior cancer were ascertained from medical records by tumor registrars. We obtained ZIP code-level sociodemographic information from the 2000 U.S. Census. The Harvard Medical School Committee on Human Studies approved this study.
Cancer-Related Imaging
We focused on cancer-related imaging-defined as imaging studies for which lung, colorectal, or prostate cancer was listed as the primary diagnosis (Appendix Table 2 , available at www.annals.org)-because we expected cancerrelated imaging for VA patients diagnosed at VA facilities to be more confined to the VA system than imaging in general (27) . We analyzed total use of imaging studies (regardless of diagnosis) in a supplemental analysis that addressed potential differences in coding practices between VA and non-VA providers but was subject to greater dual use of imaging in both systems (Appendix, available at www.annals.org).
For each patient, we assessed annual use of imaging from 2003 through 2005. We identified Current Procedural Terminology (CPT) codes that accounted for more than 95% of imaging services recorded in Medicare claims and VA utilization data in 2005 (Appendix) (34) . We excluded ancillary services (for example, contrast administration) that may be billed separately (see Appendix Table 3 , available at www.annals.org, for the final list of 197 imaging CPT codes included). From Medicare claims, we calculated a national standardized price for each CPT code equal to the national mean payment for each imaging study, covering both professional and technical components (Appendix). For each patient in each cohort, we then summed imaging studies, weighting each study by its national standardized price and removing duplicate references to the same study (that is, the same patient, CPT code, and date of service). These price-weighted counts are expressed in dollars but measure utilization (greater use of 1 study or use of a more costly study) and are unaffected by geographic variation in prices.
Context
Because the amount of medical care differs in geographic areas, policymakers have considered whether care in highvolume areas can be reduced without lowering the quality of care.
Contribution
The researchers compared the care of patients in the Veterans Affairs (VA) health care system with that of Medicare patients. They found that care was less expensive for VA than Medicare patients, but the cost of care in different areas varied as much for VA patients as it did for Medicare patients.
Caution
The study was restricted to cancer-related imaging.
Implication
Geographic variation in use may not be a reliable measure of the extent of overuse.
-The Editors
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Cancer-Related Imaging in the VA Health Care System Versus Medicare For the Medicare cohort, we summed imaging studies in Carrier and Outpatient claims files covering both inpatient and outpatient imaging. For the VA cohort, we summed imaging studies in Decision Support System National Data Extract files covering inpatient and outpatient care from VA providers, Fee Basis files covering contracted care from non-VA providers, and Medicare Carrier and Outpatient claims files covering Medicare-reimbursed care from non-VA providers (35) (36) (37) . Therefore, priceweighted utilization counts captured imaging outside of the VA system for Medicare beneficiaries in the VA cohort but not imaging in the VA system for eligible veterans in the Medicare cohort. (We could not link the Medicare cohort with VA data.) To assess the influence on our results of dual use of imaging in both Medicare and VA systems by patients in either cohort, we conducted sensitivity analyses that excluded patients from the Medicare cohort who were eligible for VA health benefits and patients from the VA cohort who received 1 or more imaging study reimbursed by Medicare (Appendix). Results after these exclusions supported our main conclusions.
Advanced Imaging for Prostate Cancer With Low Risk for Metastasis
We created 1 direct measure of low-value imaging based on the American Society of Clinical Oncology's Choosing Wisely recommendation against using advanced imaging in the staging or routine follow-up care of lowgrade prostate cancer with low risk for metastasis (24) . Specifically, we used registry data to identify patients with stage T1 or T2 prostate cancer (organ-confined disease) and a Gleason score less than 7. For each of these patients, we calculated annual price-weighted counts of advanced imaging studies for which prostate cancer was the primary diagnosis code. (Appendix Table 4 , available at www .annals.org, lists CPT codes included in this measure.)
Statistical Analysis
We used multilevel models to estimate mean differences in imaging use between Medicare and VA cohorts within HRRs, variation in use across HRRs for each cohort, and regional correlations in use between cohorts. Specifically, we fitted a linear regression model predicting annual price-weighted counts of imaging studies as a function of cohort-(VA vs. Medicare), patient-, and area-level sociodemographic characteristics listed in Table 1 ; indicators for the year of service (2003 to 2005) ; size of the Medicare population in each HRR (31); indicators for each permutation of cancer type, stage, and grade; an indicator of prior cancer; and random effects for each cohort estimating average use of imaging per patient in each HRR. We specified an unstructured covariance matrix for the 2 cohortspecific random effects to estimate an HRR-level variance for each cohort and an HRR-level correlation in mean use between cohorts (Appendix). We also fitted separate models for each type of cancer.
In a sensitivity analysis, we included Charlson comorbidity scores and an indicator of death during the year as model covariates to gauge the potential contribution of unmeasured clinical characteristics to differences between Medicare and VA patients in mean use and variation in use. We omitted Charlson comorbidity scores from our principal models because of financial incentives to code more inpatient diagnoses that are specific to Medicare and known geographic variation in Medicare coding practices (38) . To facilitate interpretation of model estimates, we also estimated mean adjusted use of cancer-related imaging for quintiles of HRRs in each cohort, using HRR-level adjusted mean use from the multilevel model to rank HRRs separately for each cohort. Finally, we decomposed mean differences between cohorts by imaging method.
Role of the Funding Source
The funding sources had no role in the design, conduct, or reporting of the study.
RESULTS
The VA cohort included 6835 men with lung, colo- . In the year of diagnosis, 33.7% of VA patients receiving at least 1 imaging study in either system received at least 1 study reimbursed by Medicare, whereas only 19.5% of VA patients receiving at least 1 cancerrelated imaging study received at least 1 cancer-related study reimbursed by Medicare (that is, 80.5% received all studies in the VA). Table 1 presents within-HRR comparisons of sociodemographic and clinical characteristics between the Medicare and VA cohorts. The VA patients were younger; were less likely to be white, be married, or have an indicator of prior cancer; had lower Charlson comorbidity scores but a similar annual mortality rate; and lived in areas with lower levels of income, education, and employment in professional occupations. They were more likely to be diagnosed with extensive small cell lung cancer but less likely to have late stage (IIIB or IV) non-small cell lung cancer, late-stage colorectal cancer, or metastatic prostate cancer.
Adjusted annual use of cancer-related imaging was lower in the VA cohort than in the Medicare cohort (mean price-weighted utilization count, $197 vs. $379 per patient; difference, Ϫ $182 [95% CI, Ϫ $208 to Ϫ$156]; P Ͻ 0.001). Lower use of computed tomography, positron emission tomography, and nuclear studies in the VA cohort accounted for 90% of this difference (Figure 1 and Appendix Table 5 , available at www.annals.org). Lower use of magnetic resonance imaging and ultrasonography
Original Research Cancer-Related Imaging in the VA Health Care System Versus Medicare contributed as well, and use of radiography was higher in the VA cohort than in the Medicare cohort. Cancer-related imaging use was lower in the VA cohort for each cancer type ( Table 2) In the VA cohort, adjusted annual use of cancer-related imaging was $237 (240%) higher per patient in HRRs in the highest quintile of use than in those in the lowest quintile. Geographic variation was moderately correlated between the 2 cohorts (r ϭ 0.53 [CI, 0.17 to 0.76]; P Ͻ 0.001), but correlations were imprecise and not consistently positive and significant across cancer types ( Table 2) . In sensitivity analyses, the difference in adjusted use of cancer-related imaging between cohorts was slightly wider after adjustment for Charlson comorbidity scores (Ϫ$185 per patient) or death (Ϫ$183 per patient) and estimates of geographic variation did not substantively differ from our main results. Adjusted total use of imaging (not just cancer-related imaging) was also significantly lower in the VA cohort than in the Medicare cohort and exhibited similarly wide geographic variation (Appendix).
DISCUSSION
In this study of older men with lung, colorectal, or prostate cancer, use of cancer-related imaging was nearly Within-region differences in adjusted imaging use between Medicare and VA cohorts are displayed by imaging method. Error bars indicate 95% CIs. CT ϭ computed tomography; MRI ϭ magnetic resonance imaging; PET ϭ positron emission tomography; VA ϭ Veterans Affairs. * Price-weighted count. Original Research Cancer-Related Imaging in the VA Health Care System Versus Medicare 50% lower for a cohort of patients in the VA health care system than for a cohort of Medicare beneficiaries in the same geographic areas. Imaging methods typically used for cancer staging and surveillance accounted for most of this difference. A measure of imaging overuse for patients with prostate cancer at low risk for metastasis detected 65% lower use in the VA cohort than in the Medicare cohort. In concert with previous research suggesting equal or better quality of cancer care in the VA than in traditional fee-forservice Medicare (14, 15) , these findings suggest more efficient use of cancer-related imaging in the VA health care system. Lower levels of cancer-related imaging in the VA cohort, however, were not associated with less geographic variation. This finding is consistent with prior studies showing similarly wide geographic variation in utilization despite differences in health care financing or organization (39 -43) and contributes to evidence that practices vary substantially within the VA system despite widespread use of clinical practice guidelines and a resource allocation system that bases area-level budgets on case-mix and localinput costs but not care intensity (29, 44 -51) . By comparing settings with distinct rather than shared payment and delivery systems, our study offers a sharper contrast than assessments of the influence of managed care on geographic variations in care for Medicare or commercially insured populations (41, 42) . In addition, using linked administrative and cancer registry data, we were able to assess actual 
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Cancer-Related Imaging in the VA Health Care System Versus Medicare www.annals.orguse in the VA system rather than allocated costs (39), identify and include Medicare-reimbursed care for VA patients, adjust for clinically relevant information (that is, tumor characteristics), and confirm that between-system differences in use included more specific differences in directly measured overuse. Thus, our study provides a robust test of whether a system achieving more efficient use of a costly set of services necessarily exhibits less geographic variation in use of those services.
In general, there are many reasons why distinguishing features of the VA system, such as structural integration of the delivery system, salaried physicians, and use of global budgets to control spending, might be associated with lower average use of health care services but not less geographic variation relative to Medicare. Because wasteful practices may be prevalent everywhere, even in areas with the most efficient providers (7, 52 ), uniformly applied systems to limit overuse may not necessarily affect high-use areas the most. Differences in provider productivity resulting from differences in training and expertise (for example, some providers ordering more services than others to achieve the same outcome) and variation in practice norms and physician beliefs may contribute equally to variation in the VA and Medicare systems (5, (52) (53) (54) (55) . Physician responses to salary incentives and performance bonuses may be as heterogeneous as their responses to fee-for-service incentives. Similarly, VA medical centers operating under budgets may prioritize services differently, leading to heterogeneity in capacity to provide a given type of service. Finally, variation in unmeasured patient characteristics could contribute to variation in risk-adjusted utilization in both systems (56) .
The correlation in cancer-related imaging between the VA and Medicare cohorts was significantly positive overall but moderate in strength; further, it was negative or weakly positive and not statistically significant for 2 of the 3 types of cancer we examined. These findings are consistent with prior research showing weak geographic correlations in other cancer-related services between the same cohorts of patients (29) and suggest that common area-level factors did not explain most of the geographic variation in each system. Due to data limitations, we could not identify specific factors explaining geographic variation in either cohort or correlations between cohorts, and we could not determine whether higher use in an area was due to greater use of inappropriate or appropriate imaging, except in the case of 1 direct measure of overuse.
Our results have important implications for assessing health system performance. In concert with prior research (14, 15, 57) , they suggest that achievement of lower average spending and better average quality for a clinical condition in a system may not be associated with less geographic variation in care intensity for that condition. Because the extent of variation may not signal the level of system efficiency, research documenting geographic variation in risk-adjusted use of medical services may not be useful for reliably characterizing the amount of wasteful care in a system. In contrast, within-system variation in performance on direct measures of overuse and quality at a facility or provider group level may be useful for targeting improvement efforts, regardless of system-wide average levels of quality and utilization (7, (45) (46) (47) . Likewise, our findings do not diminish the potential contributions of research exploring the causes of geographic variations to the understanding of physician behavior (58) .
Our study had several limitations. Our analysis was limited to imaging for patients with cancer in 2003 to 2005, but in the context of prior research on quality of cancer care for Medicare and VA patients (14, 15) , this period and category of services provided an instructive case for testing whether geographic variation necessarily reflects the extent of overuse.
Unmeasured differences in clinical characteristics between Medicare and VA patients could have contributed to differences in imaging use, but our estimates were largely unaffected by additional adjustment for observed comorbid conditions and death. Moreover, omitted clinical information would not affect our interpretation of the substantial difference in use of advanced imaging for lowgrade prostate cancer as evidence of greater overuse in Medicare. We also could not adjust for differences in VA and Medicare benefits or other unmeasured factors affecting patient demand, such as preferences for aggressive care. Because we could not observe care in the VA system for eligible veterans in the Medicare cohort, we probably underestimated differences in imaging use between cohorts. Use of Medicare-reimbursed care by VA patients may have contributed to similar geographic variation and a positive correlation between cohorts, but our analysis limited exposure of the VA cohort to the Medicare program by focusing on cancer-related imaging that was largely confined to the VA system for VA patients, as with other aspects of cancer care (27) . Moreover, sensitivity analyses suggested that dual use in both systems did not likely explain the similar extent of geographic variation within each system. Finally, less frequent coding of cancer diagnoses for cancerrelated imaging studies in the VA could have contributed to between-system differences and within-system variation, but analyses of total use of imaging supported similar conclusions.
In summary, recent evidence suggests that policies directly addressing geographic variations in service use may not achieve greater efficiency in health care (3, 5). Our study further suggests that more efficient service use may not be associated with less geographic variation. 
APPENDIX: ADDITIONAL METHODS AND RESULTS
Measuring the Use of Imaging Studies With Medicare Claims and VA Utilization Data
Using the Berenson-Eggers Type of Service classification of CPT codes to identify all imaging services (34), we selected 241 CPT codes that accounted for 95.9% of all imaging services in 2005 Medicare claims for the Medicare cohort and 95.4% of imaging services in 2005 VA utilization data for the VA cohort. After ancillary services that may be billed separately (for example, contrast administration) were excluded, 197 primary codes for imaging studies remained (Appendix Table 3 ), which accounted for 90.4% and 92.1% of instances of imaging codes in Medicare claims and VA utilization data, respectively.
From Medicare claims, we calculated a standardized price for each CPT code equal to the national mean payment for each imaging study, covering both professional and technical components. For each patient in each cohort, we then summed imaging studies across claims or utilization files, weighting each study by its standardized price and removing duplicate references to the same study (that is, same patient, CPT code, and date of service). Thus, although expressed in dollars, these price-weighted counts measure utilization and are unaffected by geographic variation in prices. Allowing a fuzzy match on the date of service (Ϯ 2 days) to remove duplicate studies did not significantly affect counts of imaging studies.
For the Medicare cohort, we summed imaging studies in Carrier and Outpatient claims files covering both inpatient and outpatient imaging. For the VA cohort, we summed imaging studies in Decision Support System National Data Extract files covering inpatient and outpatient care from VA providers, Fee Basis files covering contracted care from non-VA providers, and Medicare Carrier and Outpatient claims files covering Medicarereimbursed care from non-VA providers (35) (36) (37) . Therefore, utilization counts captured imaging outside of the VA system for Medicare beneficiaries in the VA cohort but not imaging in the VA system for eligible veterans in the Medicare cohort.
Addressing Potential Differences in Coding Practices Between the VA and Medicare
To address potential differences in the coding of imaging studies between VA and non-VA providers, we collapsed the 197 imaging CPT codes into 96 groups of similar studies (for example, magnetic resonance imaging [MRI] of the brain with contrast was grouped with MRI of the brain with and without contrast) and applied the highest standardized price in each group to all studies in the group (see Appendix Table 3 for groupings and group prices). Results were not altered substantially by this modification, which we included in our main analysis.
To address potential differences in coding of cancer diagnoses for cancer-related imaging studies, we calculated the proportion of imaging studies in Medicare claims versus VA utilization files that had a primary diagnosis of lung, colorectal, or prostate cancer as opposed to any other diagnosis. Among imaging studies for the study population, this proportion was 5 percentage points higher in VA utilization data than in Medicare claims, suggesting that the between-system difference in use of cancer-related imaging was not likely explained by less frequent coding of cancer diagnoses for imaging studies in the VA. That the proportion of studies with a cancer diagnosis was higher in the VA is also consistent with cancer care being more concentrated within the VA than care for other conditions. Moreover, in a supplemental analysis, we analyzed total use of imaging for the 2 cohorts (regardless of diagnosis) and found a pattern of results that was similar to those we report for cancer-related imaging (a significant between-system difference in imaging use but a similar extent of geographic variation in both systems). As shown in a subsequent section of this Appendix, however, analyses of total use of imaging-although unaffected by differences in diagnostic coding between the VA and Medicare-probably underestimated between-cohort differences in imaging because of greater dual use in both systems that was not directly related to cancer.
Statistical Methods
To estimate mean differences in the use of cancer-related imaging between Medicare and VA cohorts within HRRs, variation in use across HRRs for each cohort, and regional correlations in use between cohorts, we fitted the following linear mixed model:
where Y itk is the price-weighted count of cancer-related imaging studies for patient i in year t and HRR k, I M is an indicator of the Medicare cohort, I
VA is an indicator of the VA cohort, X is a vector of covariates described in the Statistical Analysis section, and u 00k and u 01k are the HRR-specific random effects for the Medicare and VA cohorts, respectively. Thus, for each cohort (I M ϭ 1, or I VA ϭ 1), the model estimates adjusted mean use overall and in each HRR. We assumed the random effects follow a bivariate normal distribution with a mean equal to 0, and we specified an unstructured covariance matrix for the random effects to estimate an HRR-level variance for the Medicare cohort ( mean use between cohorts. We assumed the residual patient variation (e itk ) followed a normal distribution and allowed a separate variance term for each cohort.
Because of the complexity of the model and the small number of repeated observations (11% of the study population with a single observation, 23% with 2, and 66% with 3), we assumed that repeated observations within a person were independent. In a sensitivity analysis, we specified a correlation matrix for the residuals that was autoregressive with respect to a person's sequence of observations (year relative to diagnosis), and estimates from this sensitivity analysis were very close to those that we report, with no change in interpretation. We used the models assuming independence in our primary approach (and for the many sensitivity analyses we conducted) because they are far more computationally efficient. In another sensitivity analysis, we restricted the cohort to the year of diagnosis (1 observation per patient for all patients and thus no repeated observations), and our conclusions were unaltered.
In addition to linear mixed models, we fitted generalized linear mixed models with a log link and a proportional-to-mean variance function and obtained substantively similar results. The HRR-level correlation in use of cancer-related imaging between the VA and Medicare cohorts was somewhat lower when estimated using this alternative specification (0.37 vs. 0.53) but well within the wide CI of the estimate from the linear model. Finally, to check the robustness of estimates to the exclusion of HRRs with small numbers of patients with cancer in either cohort, we increased the minimum threshold for inclusion to 100 personyears per HRR in each cohort (excluding 7 HRRs); results were not appreciably affected by this exclusion.
Results From Analysis of Total Use of Imaging Studies for Patients With Cancer
We repeated analyses for total use of imaging studies (not just cancer-related imaging). Like cancer-related imaging, adjusted annual total use of imaging was lower in the VA cohort than in the Medicare cohort ($1264 vs. $1368 per patient; difference, Ϫ$104 [CI, Ϫ$180 to Ϫ$27]; P ϭ 0.008) and exhibited similar variation across HRRs in the VA cohort (SD, $215 [CI, $168 to $276]) and Medicare cohort (SD, $200 [CI, $156 to $255]). In the Medicare cohort, adjusted annual use of imaging overall was $540 (47%) higher per patient in HRRs in the highest quintile of use than HRRs in the lowest quintile. In the VA cohort, adjusted annual use of imaging overall was $611 (63%) higher per patient in HRRs in the highest quintile of use than HRRs in the lowest quintile. Differences in total use of imaging studies between cohorts were not bigger than differences in cancer-related imaging use probably because of the much greater extent of dual use in both systems without cancer-related diagnoses.
Sensitivity Analysis Assessing the Effect of Dual Use
The utilization data we analyzed captured imaging outside of the VA system for Medicare beneficiaries in the VA cohort but not imaging in the VA system for eligible veterans in the Medicare cohort. (We did not have identifiers to link the Medicare cohort with VA data.) We conducted 2 sensitivity analyses to assess the influence of dual use of imaging in both Medicare and VA systems by patients in either cohort on our results. First, to gauge the effect of omitting any VA-provided care for the Medicare cohort on our results, we conducted analyses of cancer-related imaging from 2001 to 2005 for cohorts of Medicare and VA patients diagnosed in earlier years (2001 to 2002), for whom we had data on eligibility for VA health benefits. (We lacked these data for patients diagnosed in 2003 to 2004.) After patients were excluded from the Medicare cohort who were eligible for VA health benefits, the difference in adjusted annual use of cancer-related imaging between these earlier diagnosed cohorts of Medicare and VA patients grew wider by $16 (that is, use in the VA cohort was an additional $16 less than in the Medicare cohort), geographic variation in use remained similar between the cohorts, and regional correlation in use between cohorts decreased by 0.11. After this exclusion, the difference in adjusted annual total use of imaging grew wider by $73 (that is, use in the VA cohort was an additional $73 less), geographic variation in use remained similar between the cohorts, and the regional correlation in use between cohorts decreased by 0.13.
Second, from our main analyses of imaging from 2003 to 2005 for patients diagnosed in 2003 to 2004, we alternately excluded 2 groups of patients from the VA cohort: those who received at least 1 cancer-related imaging study reimbursed by Medicare (1124 person-years) (exclusion A); and those who received any imaging study reimbursed by Medicare (5434 personyears) (exclusion B). After exclusion A, the difference in adjusted annual use of cancer-related imaging between the VA and Medicare cohorts was Ϫ$230 per patient (vs. Ϫ$182 per patient in our main analysis without this exclusion) and the difference in adjusted annual total use of imaging was Ϫ$176 per patient (vs. Ϫ$103 without this exclusion). After exclusion B, the difference in adjusted annual use of cancer-related imaging between the VA and Medicare cohorts was similar to the difference after exclusion A (Ϫ$229 per patient), but the difference in total adjusted annual use of imaging between cohorts was much wider (Ϫ$357 per patient). After these exclusions, geographic variation in imaging use remained similar between cohorts; model estimates of variation in the VA cohort remained higher than but were closer to estimates of variation in the Medicare cohort. Correlation coefficients were 0.09 to 0.13 lower after these exclusions.
Thus, these findings suggest that we probably underestimated differences in imaging use-particularly differences in total use of imaging-between the Medicare and VA systems because of dual use in both systems by some patients. Excluding VA patients with Medicare-reimbursed imaging (exclusion B) may have selectively removed patients from the VA cohort with unmeasured clinical characteristics that warranted more imaging. This possibility is unlikely, however, because the addition of the Charlson comorbidity index and an indicator of death during the year as model covariates did not significantly change differences in total use of imaging between the VA and Medicare cohorts after exclusion B (as we found in our main analyses). We therefore conclude that, in the absence of dual use, differences in total use of imaging between the VA and Medicare cohorts would have been much greater than we reported in the preceding section of the Appendix and much greater than differences in use of cancer-related imaging. For example, combining the results of our sensitivity analyses and extrapolating from the results for patients diagnosed in earlier years, use of total imaging would have been $430 lower per patient in the VA cohort (Ϫ$357 ϩ Ϫ$73) and use of cancer-related imaging would have been $245 lower per patient (Ϫ$229 ϩ Ϫ$16) in the absence of dual use.
By extension, less frequent coding of cancer diagnoses for cancer-related imaging studies in the VA did not likely explain our finding of substantial between-system differences in cancerrelated imaging. If the difference in cancer-related imaging between cohorts was entirely due to differences in coding, for example, then it should have grown more than the difference in total imaging use when we excluded VA patients with imaging use reimbursed by Medicare because capture of cancer-related imaging (but not total imaging) would have been more thorough for dual users in both the VA and Medicare systems than for patients with imaging in the VA system only. We found the opposite, however, with the difference in total imaging use growing much more with this exclusion (by Ϫ$253 for total imaging vs. Ϫ$47 for cancer-related imaging-more than a 5-fold difference). In addition, if the between-system difference in cancerrelated imaging use was due to systematically lower rates of cancer diagnosis coding for cancer-related imaging studies in the VA, we would expect consistently lower use of cancer-related imaging across all methods. Use of radiography with cancer diagnosis codes, however, was substantially higher in the VA cohort than in the Medicare cohort (Appendix Table 5 ). Thus, our results were not likely driven by differences in coding practices between Medicare and the VA, and the smaller between-system differences in total imaging use (vs. the difference in cancer-related imaging use) are more consistent with greater dual use of imaging that was not directly related to cancer, or conversely, with greater concentration of cancer-related imaging within the VA for patients in the VA cohort.
These sensitivity analyses also suggest that dual use did not likely explain the observed similarity between Medicare and VA cohorts in the extent of geographic variation in imaging use but contributed to correlations that were more positive than would be seen in the absence of dual use.
Analysis of Unweighted Counts of Imaging Studies, by Method
In addition to our main analyses of price-weighted counts of utilization, we analyzed unweighted counts of cancer-related imaging studies within each imaging method. Appendix Table 5 summarizes the results of these analyses. As expected, betweensystem differences in use of higher-cost methods became relatively smaller and differences in lower-cost methods became relatively larger when analyzing unweighted rather than priceweighted counts of imaging studies. Differences in unweighted use of methods typically used for cancer staging and surveillance (computed tomography, positron emission tomography, and nuclear imaging) nevertheless remained significant and, combined, explained much of the overall difference in cancer-related imaging use. As in our main analysis of price-weighted counts, unweighted counts of cancer-related radiography were significantly higher in the VA cohort than in the Medicare cohort, suggesting possible substitution of higher-cost methods for radiography in the Medicare cohort. Geographic variation in unweighted counts was similar in both cohorts for all methods (although variation in use of positron emission tomography tended to be greater in the VA and variation in use of ultrasonography tended to be greater in Medicare), and correlations varied considerably across methods. We analyzed price-weighted counts of imaging studies in our main analyses because they better reflect between-system differences and within-system variation in resource use and can be combined across studies and methods to summarize the net effects of differences in use of a given study over no imaging and differences in use of a more costly study over a less costly study. Because different methods may substitute for one another, we caution against normative interpretations from comparisons across methods of the extent of geographic variation within the Medicare or VA cohort. For example, if use of computed tomography substitutes for use of ultrasonography to some extent, geographic variation in the use of computed tomography would lead to geographic variation in the use of ultrasonography.
Finally, in a sensitivity analysis, we also calculated the mean price of all studies done within each method and applied that to all studies in a given method when constructing summary priceweighted utilization counts across imaging methods. This adjustment, which held prices constant among studies within method while allowing price differences between methods to reflect differences in cost, did not alter our conclusions. 
